エピジェネティック治療薬の世界市場は、2023 年の 68 億ドルから 2028 年までに 98 億ドルに達し、予測期間中のCAGRは 7.7% になると推定されます。
目次
Chapter- 1: Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter- 2: Summary and Highlights
Highlights of the Market for Epigenetic Therapeutics
Chapter- 3: Market Overview and Definitions
Overview
Chapter- 4: Market Trends
Market Drivers
Market Opportunity
Market Restraints
Chapter- 5: Market Breakdown by Product Type
Introduction
PRAP Inhibitors
Kinase Inhibitors
IDH Inhibitors
HDAC Inhibitors
DNMT Inhibitors
KMT Inhibitors
Chapter- 6: Impact of COVID-19
Introduction
Impact of COVID-19 on the Medical Devices and Pharmaceutical Industries
Impact of COVID-19 on Medical Device and Pharmaceutical Product Segments
Impact of COVID-19 on Epigenetic Therapeutics Markets
Chapter- 7: Market Breakdown by Region
Market Overview and Discussion
Chapter- 8: Emerging/Upcoming Technologies
CRISPR
Antibody Drug Conjugates
Chapter- 9: Competitive Landscape
Industry Scenario
Company Shares
Chapter- 10: Patent Analysis
Patent Analysis, by Manufacturer
Chapter- 11: Pipeline Analysis
Clinical Trials Scenario
Chapter- 12: Company Profiles
ASTRAZENECA
BRISTOL-MYERS SQUIBB
CLOVIS ONCOLOGY
GSK PLC
INCYTE
IPSEN
SEAGEN
SERVIER LABORATORIES, LTD.
Chapter- 13: Appendix: Acronyms
Table 76 : Acronyms Used in this Report
